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Summary
Clinical differential diagnosis of early-onset dementia
(EOD) includes familial Alzheimer disease (FAD) and
hereditary prion disease. In both disease entities, post-
mortem brain histopathological examination is essential
for unambiguous diagnosis. Mutations in the genes en-
coding the presenilins (PS1 and PS2) and amyloid pre-
cursor protein (APP) are associated with FAD, whereas
mutations in the prion protein (PrP) gene are associated
with prion disease. To investigate the proportion of EOD
attributable to known genes, we prospectively (i.e., an-
temortem) screened these four genes for mutations by
sequencing genomic PCR products from patients with
EOD before age 60 years. Family history for dementia
was positive (PFH) in 16 patients, negative (NFH) in 17
patients, and unknown (UFH) in 3 patients. In 12 pa-
tients, we found five novel mutations (in PS1, F105L; in
PS2, T122P andM239I; and in PrP, Q160X and T188K)
and five previously reported mutations (in APP, in three
patients who were most likely unrelated, V717I; in PS1,
A79V and M139V; and in PrP, P102L and T183A) that
are all considered to be disease causing. Of these 12
patients, 9 had PFH. This indicates a detection rate of
56% (9/16) in patients with PFH. We found two mu-
tations (APP V717I) in two of the three UFH patients,
and only one mutation (PrP T188K) in 1 of the 17 pa-
tients with NFH. We conclude that because of the lack
of specific antemortem diagnostic markers for FAD and
hereditary prion disease, all four genes should be in-
cluded in a molecular diagnostic program in patients
with EOD who had PFH.
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Introduction
Heterozygous mutations in the presenilin genes (PSEN1,
PSEN2) and in the amyloid precursor protein gene
(APP) may cause early-onset autosomal-dominant fa-
milial Alzheimer disease (FAD) (MIM 104300) (Goate
et al. 1991; Levy-Lahad et al. 1995; Rogaev et al. 1995;
Sherrington et al. 1995). Clinical manifestation in Alz-
heimer disease (AD) is variable (Mayeux et al. 1985),
and differential diagnosis of early-onset dementia (EOD)
may include, in addition to FAD, prion disease (MIM
176640) associated with mutations in the prion protein
gene (PRNP) but lacking the classical neurological signs
of Creutzfeldt-Jakob disease (CJD) (MIM 123400) (Hal-
tia et al. 1994; Geldmacher and Whitehouse 1997;
Hardy and Gwinn-Hardy 1998). Clinical manifestation
also is variable in hereditary prion disease, particularly
in Gerstmann-Stra¨ussler-Scheinker disease (GSS) (MIM
137440) (Hainfellner et al. 1995; Hamasaki et al. 1998).
In both AD and prion disease, neurodegeneration is ac-
companied by cerebral deposits of amyloid and aggre-
gated tau neurofibrils. The lack of specific and unam-
biguous clinical or biochemical antemortem diagnostic
markers for both entities leads to difficult diagnostic sit-
uations in dementia patients without significant neuro-
logical signs in the early disease stage, and postmortem
histopathological evaluation is necessary for confirma-
tion of the clinical diagnosis.
In genetically relatively isolated populations, a small
number of FAD mutations have been observed repeat-
edly, for example, PS2 N141I in Volga Germans (Rogaev
et al. 1995), PS1 A79V in the Dutch population (Cruts
et al. 1998), and PS1 H163R in the Japanese population
(Kamimura et al. 1998), which may be explained by
founder effects. To determine the spectrum of mutations
and the relative contribution of the previously men-
tioned four genes, we performed a prospective molecular
diagnostic program in an ethnically heterogeneous group
of patients with EOD and no significant early neuro-
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logical signs. Such a study may help to establish criteria
for molecular diagnostics in dementia.
Subjects and Methods
DNA Samples
Genomic DNA was prepared from peripheral blood
leukocytes of 36 unrelated German, Austrian, Italian,
Hungarian, and Swiss patients with EOD and onset be-
fore age 60 years, and 3 unrelated German patients with
late-onset dementia after age 65 years. None of the pa-
tients had significant neurological signs in the early dis-
ease stage, and all had a clinical diagnosis of dementia
of unknown type or possible or probable AD. Sixteen
of the EOD patients had positive family history (PFH)
of EOD, whereas the 3 late-onset patients had PFH of
late-onset dementia. PFH was assumed if at least one
first-degree relative with dementia was reported. In some
cases, material from siblings or parents was available for
molecular analysis. DNA or blood from a total of 15
patients was sent directly to our laboratory from clinical
centers or general practitioners. Twenty-four patients
were ascertained by AD research centers (22 in Ham-
burg, Germany and 2 in Brescia, Italy). Most of the
patients seen outside our laboratory and all research-
study patients underwent full medical and neurological
examinations, cognitive evaluations, routine blood tests,
EEGs, and brain computed tomography (CT) scans.
Clinical diagnosis of possible or probable AD was made
according to criteria of the National Institute of Neu-
rological and Communicative Disorders and Stroke and
Alzheimer’s Disease and Related Disorders Associations
(McKhann et al. 1984). Postmortem histopathological
analysis in index patients (2, 7, and 13) was performed
according to the criteria recommended by the Consor-
tium to Establish a Registry for the Diagnosis of Alz-
heimer’s Disease (Mirra et al. 1991). Ethical approval
for this study was obtained from local ethics committees.
Research-study patients (if possible) and their caregivers
gave informed consent to participate.
Sequencing and Genotyping
Mutation analysis was done on genomic DNA by di-
rect sequencing of both strands of PCR-amplified coding
exons of PSEN1, PSEN2, exons 16 and 17 of APP, and
the single coding exon of PRNP. Primer sequences were
designed according to GenBank entries and are available
on request. Amplification was done by a universal
“touch down” protocol, and amplicons were sequenced
by fluorescent dye dideoxy terminators, as described
elsewhere (Finckh et al. 1998). Mutation screening was
stopped if a known and most likely disease-causing mu-
tation was identified in any patient. In all other patients,
all four previously mentioned genes were analyzed. All
sequence changes were confirmed by restriction-enzyme
digestion or allele-specific PCR (ASP) (table 1). PRNP
haplotypes were determined by selective sequencing of
single alleles after restriction digestion at polymorphic
codon 102 (Owen et al. 1989).
Results
In 14 patients, we found a total of 12 different mu-
tations in PSEN1, PSEN2, APP, and PRNP (fig. 1 and
table 1). Of the 12 mutations, 5 were previously un-
described and 7 were known. None of the five novel
mutations were present on 100 control chromosomes.
Of the 12 mutations reported here, 2 (PS1 E318G, PrP
del r34) are considered nonpathogenic polymorphisms
(see following). The 10 remaining mutations, in a total
of 12 patients, affect evolutionarily highly conserved res-
idues. Of these 12 patients, 9 had PFH of EOD (fig. 1
and table 2). No mutation was found in the four genes
studied in the three patients with late-onset dementia
and PFH for late-onset dementia.
PS1 A79V
Age at onset was ∼58 years in patient 1. The disease
course was initially mild: she retired from work at age
60 years and lived in her own house until age 72 years,
when she was admitted to a nursing home. Since age 77
years, she has been bedridden. At age 78 years, there is
severe dementia. A similar age at onset and a 10-year
duration of the disease were reported for the patient’s
mother. Several maternal relatives were said to be af-
fected by EOD. However, no written reports were avail-
able. Several Dutch FAD cases with the PS1 A79V mu-
tation, most likely the result of a common founder, and
a clinical course similar to that of our patient have been
reported recently (Cruts et al. 1998).
PS1 F105L
This novel PSEN1 mutation was found in patient 2,
whose age at onset of disease was 52 years. Residue 105
is in the hydrophilic loop 1, immediately adjacent to
transmembrane domain 1 of PS1. The diagnosis of prob-
able AD was first documented at age 59 years, when her
mini-mental state-examination (MMSE) (Folstein et al.
1975) score was 13 of 30. At age 60 years, she developed
Parkinson-like symptoms. She died in a fully demented
and bedridden state at age 63 years. Autopsy of the brain
excluded Parkinson disease and confirmed the suggested
diagnosis of AD by demonstration of numerous neu-
rofibrillary tangles (NFT) and senile plaques (SP) in hip-
pocampus in addition to disseminated cortical SP. EOD
was reported both for the mother and maternal grand-
mother of the patient.
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Table 1










1 G GCCrGTC PS1 A79V HhaI Early ∼58 NA
2 G TTTrTTG PS1 F105Lf Bst1107 I Early ∼52 NA
3 G ATGrGTG PS1 M139V NlaIII Early 32 NA
4 G GAArGGA PS1 E318Gg ASP Negative 53 ND
5 G GAArGGA PS1 E318Gg ASP Late 53 NA
6 G ACGrCCG PS2 T122Pf AciI Early 46 
del 24bp PrP del r34h Sequencing 
7 I ATGrATA PS2 M239If HaeIII Early 58 
8 G GTCrATC APP V717I BclI Early ∼50 NA
9 G GTCrATC APP V717I BclI Unknown 53 ND
10 T GTCrATC APP V717I BclI Unknown 54 ND
11 G CCGrCTG PrP P102L DdeI Early 40 
12 A CAArTAA PrP Q160Xf  DdeI Early 32 
13 G ACArGCA PrP T183A ASP Early 40 
14 A ACGrAAG PrP T188Kf ASP Negative 59 ND
a G = Germany; T = Thailand; I = Italy; A = Austria.
b Confirmation of mutation by restriction endonuclease digestion ( / = gain / loss of cleavage site, respectively)
or allele-specific PCR (ASP).
c Early = EOD; late = late-onset dementia reported in first-degree relatives of the index patient; unknown =
family history unknown or not informative; negative = family history negative for dementia.
d Age at onset of dementia in index patient.
e NA = No family material available for segregation analysis; ND = unknown or negative family history;  =
cosegregation;  = no cosegregation of EOD with the mutation.
f Mutation not described previously.
g This mutation affects an evolutionarily-not-conserved residue, and it seems to be a nonpathogenic poly-
morphism.
h This in-frame deletion seems to be a nonpathogenic polymorphism.
PS1 M139V
This PSEN1 mutation was found in patient 3, whose
age at onset of disease was 32 years. At age 39 years,
various neurological symptoms—including extrapyr-
amidal hyperkinetic movement disorders, ataxia, and in-
continence—were documented, and she was admitted to
a nursing home. From age 40 years, she needed a wheel-
chair and had grand mal epileptic seizures. At age 45
years, she is bedridden and presents akinetic mutism, a
virtually apallic syndrome, spastic tetraplegia, and fre-
quent myoclonic jerks. This severe disease course is sim-
ilar to those reported previously for other patients car-
rying M139V (Fox et al. 1997; Hull et al. 1998). Both
the patient’s father and paternal grandfather died in a
demented state at age 41 years and 46 years, respectively,
and for both, an autopsy-based histopathological con-
firmation of AD was reported by demonstration of SP
and NFT.
PS1 E318G
This nonsynonymous PSEN1 change was found in
two patients (4, 5) with negative family history for EOD.
The father of one of the patients had late-onset dementia.
PS1 E318G seems to be a nonpathogenic polymorphism
of an evolutionarily-not-conserved residue that has re-
peatedly been found in nondemented control subjects
(Aldudo et al. 1998; Mattila et al. 1998; Dermaut et al.
1999). In line with this assumption, and in contrast to
other PSEN1 mutations, E318G was shown not to affect
beta-catenin trafficking (Nishimura et al. 1999).
PS2 T122P
This PSEN2 mutation was identified in patient 6,
whose age at onset of disease was 46 years. She retired
from work at age 47 years. At age 49 years, she had an
MMSE score of 16, and the clinical diagnosis of prob-
able AD was presented. The observed clinical course was
similar to that of her mother and her maternal grand-
mother, who died at ages 48 years and 51 years, re-
spectively. The mutation was not found in her healthy
(at age 81 years) father. Family history suggests a con-
stant pattern of phenotype expression and a high pen-
etrance of T122P unlike M239I (see following) and the
previously reported mutations N141I and M239V of
PSEN2 (Levy-Lahad et al. 1995; Rogaev et al. 1995).
PrP del r34
In addition to the PS2 T122P mutation, patient 6 car-
ried a heterozygous 24-bp in-frame deletion in PRNP
(del r34). This deletion removes part of the last two of
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Figure 1 Pedigrees of the families with history of EOD and most likely pathogenic mutations described in this study. Numbers above the
pedigree symbols indicate actual age or age at death. Numbers below the filled symbols indicate the probable age at onset in index patients
(arrow) or their affected relatives. Results of mutation screening on the samples available for molecular analyses are indicated as  (mutation
found) and  (mutation excluded) below the pedigree symbols. Available histopathological autopsy results of index patients are indicated by
an asterisk (*). Reports about previous histopathological analyses in affected relatives are indicated by a pilcrow (¶).
the five proline-rich octapeptide repeat elements (r1-r2-
r2-r3-r4) in PrP (Kretzschmar et al. 1986). In patient 6,
del r34 was in cis with the M129-encoding allelic variant
of PrP 129M/V (Owen et al. 1989). As a result of the
high sequence similarity of the repeat elements, it is im-
possible to determine the precise location of the deletion
that may be identical to previously reported PRNP de-
letions found both in patients with dementia and in non-
demented subjects (Palmer et al. 1993; Perry et al. 1995;
for literature, see also “The Official Mad Cow Disease
Home Page”). Both the patient and her father were het-
erozygous for M129V. The patient’s father, who was not
demented at age 81 years and did not carry the PS2
mutation, also carried M129 in cis with del r34. There-
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Table 2
Frequency of Pathogenic Mutations Detected in 39 Unrelated
Patients with Dementia Grouped According to Onset and
Family History
Clinical Diagnosis
of Index Patient Family History n
Pathogenic
Mutations
EOD EOD 16 9
Negative for EOD 17 1
Unknown 3 2
Late-onset dementia Late-onset dementia 3 0
fore, del r34 is likely a nonpathogenic polymorphism.
This conclusion is supported by a report on cosegre-
gation of dementia with PS1 H163R but not with a 24-
bp PRNP deletion in two siblings with mixed neuro-
pathological features of AD and CJD (El Hachimi et al.
1996).
PS2 M239I
We have identified another yet-undescribed PSEN2
mutation (M239I in PS2 TM5) in the index patient (pa-
tient 7) of an Italian family with three affected siblings.
Patient 7 had a mild disease course with onset at age 58
years. He died, at age 65 years, of a ruptured aortic
aneurism. AD was histopathologically confirmed at au-
topsy. In this family, five siblings carried PS2 M293I, but
only three of them had AD. Both unaffected mutation
carriers are at least as old as their affected siblings (fig.
1) and are considered to be at risk for later-onset de-
mentia. The two younger affected siblings of patient 7
have a more severe course and earlier onset (U. Finckh,
unpublished data). This phenotypic variability is similar
to that of the previously reported PS2 mutations M239V
in an Italian and N141I in Volga German kindreds
(Levy-Lahad et al. 1995; Rogaev et al. 1995; Bird et al.
1996; Sherrington et al. 1996).
APP V717I
In three most likely unrelated patients with dementia
(patients 8–10), we identified the “London” mutation
APP V717I (Goate et al. 1991). Patient 8, with PFH and
onset at ∼50 years of age, had an MMSE score of 3 at
age 57 years, when her CT scan revealed a marked brain
atrophy that was most pronounced in the temporal lobes
and without signs of ischemic infarctions. No family
material was available (fig. 1). Patient 9, with onset at
age 53 years, has an MMSE score of 25 at age 56 years.
His parents had no dementia, but died before age 50
years. Family history was unavailable. Patient 10, with
a probable dementia onset at age 54 years, has an MMSE
score of 14 at age 56 years. She is a Thai immigrant to
Germany and no detailed information about her family
history was available.
PrP P102L
This mutation in PRNP codon 102 was found in two
siblings, both with onset at age 40 years. Both siblings
shared the GSS haplotype PrP L102 in cis with M129
(Hsiao et al. 1989; Hainfellner et al. 1995), and were
heterozygous for M/V at codon 129. At age 43 years,
the affected brother of the index patient had a diagnostic
antemortem brain biopsy of the right prefrontal cortex.
Histopathologically (staining techniques: HE, trichrom.
Masson, PAS, Bielschowsky) were found some atrophic
neurons, multiple small and larger-sized amorphic am-
yloid areas with only few glial reactions surrounding
them, and neurofibrillary aggregates in some single neu-
rons. The white matter was described as spongious, with
some areas of discrete reactive glial proliferation. All of
these together were interpreted as signs of primary cor-
tical atrophy of Alzheimer type. The patient died at age
54 years; no autopsy was done. Analysis of the pedigree
revealed several relatives with ataxia and largely variable
clinical phenotype characteristic for GSS.
PrP Q160X
In an Austrian family, we identified the novel nonsense
mutation PrP Q160X. This mutation, in cis with PrP
M129, was found both in the index patient (patient 12),
with onset of dementia at age 32 years and a severe and
rapidly progressing course, and in his elder brother, with
onset at age 48 years and a mild course. The wild-type
allele of the younger brother encodes M129 and that of
the elder brother encodes V129. Repeated EEGs from
patient 12 done at at ages 35, 36, 37, and 38 years were
slightly abnormal, with diffuse theta increment and in-
termittent theta groups but without hints of seizures.
Both cranial CT at age 35 years and magnetic-resonance
imaging (MRI) at age 37 years showed severe ventricular
and sulcal enlargement. Cranial MRI of the elder
brother, done at age 55 years, showed almost normal
findings with only slight cerebellar atrophy. So far, after
disease durations of 6 and 8 years, respectively, no neu-
rological sign of CJD or ataxia has been observed in the
two brothers. Their father also had dementia with onset
at age 48 years and a severe course resembling that of
the index patient. The father died with pneumonia at
age 60 years. Pathology reports from 1980 noted a re-
duced brain weight of 1,200 g, diffuse cortical atrophy,
extensive enlargement of ventricles, little arteriosclerosis
of brain vessels, and no stenosis of the carotid arteries.
No microscopic analyses were done.
PrP T183A
Patient 13 represents the second case with this mu-
tation first described in a Brazilian family with EOD and
histopathologically confirmed spongiform encephalo-
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pathy (Nitrini et al. 1997). The clinical course in patient
13 was observed over a period of 4 years. Because there
were no neurological signs of CJD, the clinical diagnosis
of possible AD was made. The patient died at age 44
years, and autopsy confirmed hereditary prion disease
by demonstration of spongiform encephalopathy (U.
Mann, unpublished data).
PrP T188K
We discovered this novel missense mutation in PRNP
codon 188 in a 59-year-old patient (patient 14) with a
NFH. Initially, leading signs of the disease were dys-
phasia along with dementia. In this patient, the disease
is rapidly progressing and has reached a most severe
dementia in !1 year.
Discussion
Mutation Detection Rates
The results summarized in this report, together with
those of other authors, suggest that 10 of the 12 different
mutations detected in 14 of a total of 36 patients with
EOD are disease causing. Our data indicate a high prev-
alence of pathogenic mutations in APP, PSEN1, PSEN2,
or PRNP in patients with onset of dementia at age !60
years and PFH of EOD. Of the 16 patients with PFH,
9 (56%) carried pathogenic mutations, whereas only 1
of 17 patients with NFH carried a pathogenic mutation
that was in PRNP (see table 2). The latter patient also
has clinical signs atypical of AD, and he most likely has
prion disease.
The high frequency of mutations in the three known
FAD genes of patients with PFH extends the data ob-
tained in Dutch and Japanese FAD studies that reported
detection rates by PCR-SSCP of 18% and 20%, respec-
tively (Cruts et al. 1998; Kamimura et al. 1998). In these
studies, only PSEN1 mutations—and no mutations in
PSEN2 or APP—were found. In the relatively homo-
geneous Dutch and Japanese populations, the frequency
and spectrum of disease mutations may be different from
that of a more heterogeneous population. This view is
supported by the recurrent finding of PS1 A79V in the
Dutch population, pointing to a possible founder effect
(Cruts et al. 1998) and the repeated finding of PS1
H163R in the Japanese population (Kamimura et al.
1998). The data from our multinational patient sample
suggest an extensive genetic heterogeneity of FAD. Fur-
thermore, our data suggest that, in a well-selected group
of patients, over 50% of the genetic causes of EOD
resembling FAD, or 46% of early-onset FAD, can be
readily identified.
PRNP versus FAD Mutations
Patients with dementia who had mutations in PSEN1,
PSEN2, or APP most likely have FAD, whereas muta-
tions in PRNP lead most likely to prion disease. In all
three deceased index patients of our prospective study,
molecular prediction was confirmed histopathologically
at autopsy. An affected sibling of one of our index pa-
tients (11) with the well-known GSS mutation, PrP
P102L, had a biopsy-based histopathological diagnosis
of AD in 1987, 2 years before the first report on a fa-
milial PrP mutation appeared (Hsiao et al. 1989). In up
to 10% of histopathologically confirmed CJD cases, AD-
typical neuropathologic changes can also be seen (Hain-
fellner et al. 1998). So the limited amount of antemortem
brain biopsy material available and the lack of PrP-spe-
cific immunocytochemistry may explain the interpreta-
tion of the findings as AD in this patient.
The observation of 4 mutations in PRNP, among a
total of 12 pathogenic mutations in patients with EOD,
suggests an important overlap in clinical symptoms be-
tween FAD and hereditary prion disease. Together with
the findings of other studies that prion disease and AD
pathology may be present simultaneously (El Hachimi
et al. 1996; Hainfellner et al. 1998), our data support
the idea that AD and prion disease may occur jointly in
individual patients.
PrP Q160X
The M/V polymorphism at PrP residue 129 is known
to modify phenotype expression of several prion disease
alleles (Goldfarb et al. 1992; Barbanti et al. 1996; Young
et al. 1997). A premature stop of PRNP at codon 145
(Y145X) was previously found in an isolated case with
unknown family history and a clinical diagnosis of AD
but with a postmortem diagnosis of cerebral PrP amyloid
angiopathy (Kitamoto et al. 1993; Ghetti et al. 1996).
RT-PCR results (Kitamoto et al. 1993) and protein data
(Ghetti et al. 1996) suggested expression of the mutated
allele and its involvement in cerebral PrP pathology. For
Q160X, however, we assume an analogy that cannot be
investigated in vivo in the two brothers carrying this
mutation. However, our finding of the nonsense muta-
tion in both brothers and the PFH strongly support the
view that a PrP stop mutation may well be causative in
autosomal-dominant dementia.
Conclusions
The data presented in this study show the importance
of diagnostic sequencing of APP, PSEN1, PSEN2, and
PRNP in patients with EOD and PFH but without neu-
rological signs in the early phase of the disease and with-
out histopathological analysis. So as not to miss specific
treatments of known causes of dementia, and for proper
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clinical and genetic counseling, early and disease-specific
diagnosis of EOD is essential. This need will be even
more urgent with the upcoming more efficient or even
preventive specific treatment of AD or prion disease.
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